Determination of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in plasma by direct injection into a coupled column liquid chromatographic system

被引:16
|
作者
Bielenstein, M
Astner, L
Ekberg, S
机构
[1] Natl Corp Swedish Pharm, Cent Lab, S-10514 Stockholm, Sweden
[2] Swedish Orphan AB, S-11160 Stockholm, Sweden
[3] Sahlgrens Univ Hosp, Dept Internal Med, RCEM, S-41345 Gothenburg, Sweden
来源
JOURNAL OF CHROMATOGRAPHY B | 1999年 / 730卷 / 02期
关键词
direct injection; coupled columns; 2-(2-nitro-4-triffuoromethylbenzoyl)-1,3-cyclohexanedione;
D O I
10.1016/S0378-4347(99)00199-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The chemical substance 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) is in clinical use for the treatment of hereditary tyrosinemia type 1. In the present study, the plasma concentration of NTBC was determined by a coupled column liquid chromatographic method. A 20-mu l volume of plasma was diluted with phosphate buffer, pH 2, and injected into a small precolumn (BioTrapAcid C-18) with a mobile phase containing sulfuric acid. The precolumn was based on the restricted access principle, i.e., retention of NTBC within the lipophilic pores, while polar and large endogenous compounds were eluted with the void volume. NTBC was transferred to the analytical column using a mobile phase with a high content of acetonitrile. The compound was monitored by UV detection at 278 nm. The standard curve was linear between 0.3 and 69 mu M, and the between-day precision (RSD) was 3% (n=6 days) at 13.8 mu M and 14% (n=6 days) at 0.3 mu M NTBC in plasma. The quantitation Limit was approximately 0.3 mu M using 20 mu l of plasma. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:177 / 182
页数:6
相关论文
共 50 条
  • [1] Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)
    Holme, E
    Lindstedt, S
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 1998, 21 (05) : 507 - 517
  • [2] Characterization of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione resistance in pyomelanogenic Pseudomonas aeruginosa DKN343
    Ketelboeter, Laura M.
    Bardy, Sonia L.
    [J]. PLOS ONE, 2017, 12 (06):
  • [3] The effectiveness of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) as a therapeutic agent for tyrosinemia-I: The US experience
    Scott, CR
    Sniderman, LC
    Smith, CO
    Feldman, K
    [J]. PEDIATRIC RESEARCH, 2000, 47 (04) : 168A - 168A
  • [4] From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug
    Lock, EA
    Ellis, MK
    Gaskin, P
    Robinson, M
    Auton, TR
    Provan, WM
    Smith, LL
    Prisbylla, MP
    Mutter, LC
    Lee, DL
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 1998, 21 (05) : 498 - 506
  • [5] CAPILLARY ELECTROPHORESIS FOR THE CONTROL OF THE OPTIMAL DOSE OF NTBC (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) IN SERUM SAMPLES OF HEREDITARY TYROSINEMIA TYPE I PATIENTS
    Cansever, M. Serif
    Zeybek, A. Cigdem Aktuglu
    Erim, F. Bedia
    [J]. MOLECULAR GENETICS AND METABOLISM, 2009, 98 (1-2) : 33 - 33
  • [6] Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC)
    Luijerink, MC
    Jacobs, SMM
    van Beurden, EACM
    Koornneef, LP
    Klomp, LWJ
    Berger, R
    van den Berg, IET
    [J]. JOURNAL OF HEPATOLOGY, 2003, 39 (06) : 901 - 909
  • [7] Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients
    Herebian, Diran
    Spiekerkoetter, Ute
    Lamshoeft, Marc
    Thimm, Eva
    Laryea, Maurice
    Mayatepek, Ertan
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (14-15): : 1453 - 1459
  • [8] Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione
    Molchanov, Sergey
    Gryff-Keller, Adam
    [J]. ACTA BIOCHIMICA POLONICA, 2009, 56 (03) : 447 - 454
  • [9] Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)
    Raimann, Erna
    Cornejo, Veronica
    Arias, Carolina
    Francisco Cabello, Juan
    Castro, Gabriela
    Fernandez, Eloina
    de la Parra, Alicia
    [J]. REVISTA MEDICA DE CHILE, 2012, 140 (02) : 169 - 175
  • [10] Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione
    Kavana, M
    Moran, GR
    [J]. BIOCHEMISTRY, 2003, 42 (34) : 10238 - 10245